NCT02370498View on ClinicalTrials.gov

A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061)

PHASE3CompletedINTERVENTIONAL
Enrollment

592

Participants

Timeline

Start Date

May 11, 2015

Primary Completion Date

October 26, 2017

Study Completion Date

June 10, 2021

Conditions
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Interventions
BIOLOGICAL

pembrolizumab

200 mg administered as IV infusion on Day 1 of each 21-day cycle.

DRUG

paclitaxel

80 mg/m\^2 administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02370498 - A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061) | Biotech Hunter | Biotech Hunter